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Abstract: The aim of this study was to fabricate camptothecin/iron(III) oxide 
(CPT/Fe2O3)-loaded poly(D,L-lactide-co-glycolide) (PLGA) composite mats to modulate 
the CPT release and to improve the structural integrity and antitumor activity of the released 
drug. The CPT/Fe2O3-loaded PLGA ultrafine fibers were prepared for the first time by 
electrospinning a composite solution of CPT/Fe2O3 and neat PLGA (4 weight percent). The 
physicochemical characterization of the electrospun composite mat was carried out by scanning 
electron microscopy, energy dispersive X-ray spectroscopy, electron probe microanalysis, 
thermogravimetry, transmission electron microscopy, ultraviolet-visible spectroscopy, and 
X-ray diffraction pattern. The medicated composite fibers were evaluated for their cytotoxicity 
on C2C12 cells using Cell Counting Kit-8 assay (Sigma-Aldrich Corporation, St Louis, MO). 
The in vitro studies indicated a slow and prolonged release over a period of 96 hours with 
mild initial burst. Scanning electron microscopy, thermogravimetry, and X-ray diffraction 
studies confirmed the interaction of CPT/Fe2O3 with the PLGA matrix and showed that the 
crystallinity of CPT decreased after loading. Incorporation of CPT in the polymer media 
affected both the morphology and the size of the CPT/Fe2O3-loaded PLGA composite fibers. 
Electron probe microanalysis and energy dispersive X-ray spectroscopy results confirmed well-
oriented composite ultrafine fibers with good incorporation of CPT/Fe2O3. The cytotoxicity 
results illustrate that the pristine PLGA did not exhibit noteworthy cytotoxicity; conversely, 
the CPT/Fe2O3 composite fibers inhibited C2C12 cells significantly. Thus, the current work 
demonstrates that the CPT/Fe2O3-loaded PLGA composite fibers represent a promising 
chemotherapeutic system for enhancing anticancer drug efficacy and selectively targeting 
cancer cells in order to treat diverse cancers.
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Introduction
Cancer is a major growing public problem and is the second main cause of deaths after 
cardiovascular diseases. It is a disease characterized by unregulated cell proliferation. 
Cancer can develop in almost any organ or tissue of the body, however, the efficient 
cure of cancer is still a challenge in disease treatments. Camptothecin (CPT) is a potent 
cytotoxic agent and shows anticancer activity for solid malignancies. CPT and its analogs 
show anticancer activity against colon, breast, liver, lung, prostate, and pancreatic cancer 
cells. It inhibits DNA topoisomerase I.1,2 Two CPT analogs, Hycamtin® and Camptosar®, 
have received Food and Drug Administration approval for the treatment of ovarian and 
lung cancers and for colorectal cancer, respectively.3,4 CPT was first isolated by Wall et al5 
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from the wood Camptotheca acuminate Decaisne (Nyssaceae), 
a plant native to mainland China. After its successful isolation 
and characterization from the oriental tree C. acuminata, 
it aroused tremendous interest due to its splendid antitumor 
activity. Despite its high activity, it has limited therapeutic use. 
This is due to its poor aqueous solubility, serious side effects, 
and opening of the lactone ring at physiological pH to yield 
the carboxylate form which is inactive.6,7 CPT is commonly 
given as a sodium salt of the carboxylate form in the clinic to 
overcome the poor solubility of the lactone form; this requires 
higher dosing which may lead to additional toxic reactions. 
To overcome the solubility and stability problems, a series of 
CPT analogs have been synthesized and a few have entered the 
clinic.8 Simultaneously, considerable interest has been devoted 
towards the design of new drug delivery systems with the aim 
to specifically target the drug to a tumor site, such that the drug 
is released at a controlled rate and at the desired time.
Nanotechnology offers promising applications in cancer 
treatments due to the unique properties of nanostructures. 
Drug-coated polymer nanoparticles can efficiently increase 
the intracellular accumulation of anticancer drugs.9 Although 
diverse delivery systems have been developed for the 
insoluble lactone form of CPT and its derivatives,10,11 the pos-
sibility of iron(III) oxide (Fe2O3) loaded with CPT embedded 
in poly(D,L-lactide-co-glycolide) (PLGA) ultrafine fibers 
(CPT/Fe2O3-PLGA) for controllable release has hitherto 
not been investigated. The purpose of the current study was 
to encapsulate CPT in a novel carrier leading to low and 
controllable release to maintain the structural integrity and 
antitumor activity of drug as long as possible. PLGA was 
selected as it is a Food and Drug Administration-approved 
biodegradable and biocompatible copolymer. PLGA, with 
different glycolic acid to lactic acid ratios, produces fibers 
with suitable mechanical properties and a wide range of 
diameters and degradation rates.12 The electrospinning pro-
cess provides marvelous opportunities for fabricating fibers 
with a diameter from nanometers to a few micrometers.13–15 
In addition to the widespread applications in tissue engi-
neering, electrospun nanofibers can also be used as a drug 
delivery system. Drug delivery with polymer nanofibers is 
based on the principle that the dissolution rate of the drug 
increases with increased surface area of both the drug and 
the corresponding carrier. Besides their large surface area to 
volume ratio, polymer nanofibers also have other additional 
advantages. For example, unlike common encapsulation 
involving some complicated preparation process, therapeutic 
compounds can be easily incorporated into the carrier 
polymers using simple electrospinning. These electrospun 
nanofibers may be beneficial as cancer treatments through 
passive tumor targeting due to the enhanced permeability and 
retention effect.16,17 Furthermore, for biomedical applications 
the use of particles that present superparamagnetic behavior 
at room temperature is preferred. The magnetic nanoparticles 
of iron oxides, ie, magnetite and maghemite, represent the 
suitable candidates for preparation of magnetic nanocom-
posites owing to their unique applications such as vehicles 
for drug delivery,18 nontoxicity, biocompatibility, biode-
gradability properties, and low price. To use these magnetic 
nanoparticles in biomedical applications, they often have 
to be modified with biocompatible compounds.19 Scientists 
have accomplished this by either coating the magnetic nano-
particles with a layer of biodegradable polymers or evenly 
distributing a polymer matrix throughout the nanoparticles.20 
Magnetic drug targeting has been used to improve localized 
drug delivery and also enhance drug-therapeutic efficiency 
in various tumors.21
Considering the unique properties of Fe2O3 nanoparticles 
and PLGA nanofibers, the current study attempted to synthe-
size CPT/Fe2O3-PLGA composite ultrafine fibers via simple 
and cost-effective electrospinning technique. By blending a 
drug into a polymeric carrier matrix, it is dispersed, meaning 
that the crystal lattice energy has already been overcome. In 
addition, the polymer carrier can stabilize the formed amor-
phous drug dispersion through specific molecular interactions 
and the tendency for the drug to recrystallize is made kineti-
cally unfavorable for a long enough period to make the mate-
rial pharmaceutically useful.22 Thus, the combination of the 
chemotherapeutic agent (CPT) with composite solution (Fe2O3 
magnetic nanoparticles and PLGA) is an attractive strategy 
to overcome the limitations of conventional cancer treatment. 
Moreover, the present project demonstrates the possibility 
of a designed composite matrix for enhanced adsorption of 
an anticancer drug in target cancer cells. To the best of the 
authors’ knowledge, an efficient delivery system that uses a 
novel composite of PLGA ultrafine fibers and Fe2O3 magnetic 
nanoparticles was developed here for the first time in order 
to realize the efficient accumulation of the anticancer drug 
CPT in target cancer cells. The resulting medicated nanofibers 
were characterized with regard to morphology, drug release 
behavior, and cytotoxicity on mouse myoblast C2C12 cells.
Material and methods
Materials
Iron(III) nitrate nonahydrate (Fe(NO3)3 ⋅ 9H2O, .98.5%) and 
ammonia solution (28%–30%) were purchased from Samchun 
Chemical Co, Ltd (Seoul, Korea). Cetyltrimethylammonium 
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bromide (98%) was purchased from Sigma-Aldrich 
Corporation (St Louis, MO). PLGA (82:18 to 88:12 molar 
ratio; L-lactide: glycolide; inherent viscosity 2.5–3.5 
dL/g) was obtained from Boehringer Ingelheim Pharma 
GmbH (Ingelheim, Germany). Dichloromethane and 
N,N-dimethylformamide (analytical grade; Showa Chemi-
cals, Tokyo, Japan) were used as solvents without further 
purification. CPT was purchased from Sigma-Aldrich (95%). 
All other chemicals and solvents were of analytical grade and 
purchased from Sigma-Aldrich unless otherwise indicated.
Preparation of magnetic  
Fe2O3 nanoparticles
Fe2O3 nanoparticles were prepared by the hydrothermal 
method as described elsewhere17 with suitable modifications. 
In a typical procedure, 5.0 g iron(III) nitrate nonahydrate was 
dissolved in 100 mL distilled deionized water. Then, 0.5 g 
cetyltrimethylammonium bromide was added to the aqueous 
iron nitrate solution and mixed under vigorous magnetic stir-
ring for 30 minutes at room temperature. The solution was 
maintained at pH ∼7 by adding ammonia. The suspension 
(100 mL) was subsequently transferred into a Teflon-lined 
stainless steel autoclave (R-201 Series, Reaction Engineer-
ing, Inc., South Korea) (200 mL capacity), sealed, and 
maintained at 150°C for 24 hours. The reaction mixture was 
cooled to room temperature and the precipitate was washed 
with distilled water. The precipitate was then separated by 
filtration and dried in an oven at 80°C overnight. Finally, the 
as-synthesized material was calcined at 600°C for 5 hours.
Preparation of pristine and CPT/Fe2O3-
PLGA composite ultrafine fiber mats
The synthesis of CPT/Fe2O3-PLGA composite ultrafine fibers 
was carried out by using as-synthesized Fe2O3 nanoparticles 
and analytical grade extra pure (95%) CPT. Typically, 
PLGA (4 weight percent) was dissolved in dichloromethane: 
N,N-dimethylformamide (80:20 volume/volume) under mag-
netic stirring at room temperature overnight. A predetermined 
amount of CPT (∼5 mg) and synthesized Fe2O3 (5% weight/
weight based on the polymer) were added into the PLGA 
solution. The composite solution was stirred for ∼2 hours 
at room temperature for proper mixing. The blend solution 
of the polymer, Fe2O3 and CPT was transferred to a 10 mL 
syringe. A copper pin connected to a high voltage generator 
was inserted into the solution as a positive terminal whereas 
a ground iron drum covered by polyethylene sheet served 
as counter electrode. The solution was kept in the capillary 
by adjusting the inclination angle. A voltage of 15 kV was 
applied to this solution. The distance between the syringe 
needle tip and collector was fixed at 10 cm. The as-spun 
(pristine and composite) mats were initially dried at room 
temperature and thereafter maintained in a vacuum for 
24 hours to remove residual solvents and finally stored at 
4°C away from light for further analysis.
Characterization
X-ray diffraction (XrD) analysis
The XRD patterns of synthesized Fe2O3 nanoparticles and 
pristine, medicated CPT/Fe2O3-PLGA composite ultrafine 
fibers were recorded on a X-ray diffractometer (D/MAX 
2500, Rigaku Corporation, Tokyo, Japan) with copper Kα 
radiation (λ = 1.540 Å) over Bragg angles ranging from 
10–80 degrees. The operating voltage and current was main-
tained at 30 kV and 40 mA, respectively.
Morphology of Fe2O3 nanoparticles and pristine 
CPT/Fe2O3-PLGA composite fibers
The surface morphology of Fe2O3 nanoparticles, pristine 
PLGA ultrafine fibers, and the medicated composite was 
studied by using scanning electron microscopy (SEM) 
(S-7400; Hitachi High Technologies, Tokyo, Japan). The 
samples were uniformly sprayed on carbon tape, platinum 
coating was applied for 10 seconds onto the synthesized 
nanofibers, and the images were acquired at various 
  magnifications. The fiber diameter was measured directly 
from SEM images. The microscopic features of the composite 
fibers were examined under transmission electron micros-
copy (TEM) (H-7650; Hitachi). The samples for analysis 
were prepared by placing copper grids near to the syringe 
microtip opening for a few seconds to collect the fibers.
Drug loading content and encapsulation efficiency
The CPT content and encapsulation efficiency in the CPT/
Fe2O3-PLGA composite mat was determined by following a 
previously established method23 with suitable modifications. 
Briefly, an exactly weighed amount of composite fibers was 
dissolved in dichloromethane: N,N-dimethylformamide 
(4:1 volume/volume; 2 mL) solvent mixture and gently 
stirred for ∼10 minutes at room temperature. The resulting 
suspension was properly diluted with the aforementioned 
solvent mixture (10 mL) and vortexed for ∼3 minutes. From 
this solution, 1 mL was transferred to a test tube using a 
micropipette. To this 1 mL, 5 mL dichloromethane solvent 
was added, which resulted in a clear solution. The CPT 
concentration in the suspension was determined by ultraviolet 
(UV) absorption at the wavelength of 295 nm with reference 
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to a calibration curve on a UV-visible (UV-Vis) spectropho-
tometer (HP 8453; Agilent Technologies, Santa Clara, CA) 
equipped with a computer. The encapsulation efficiency (%) 
was estimated as being the percentage of CPT incorporated 
into the composite fibers in relation to the amount of drug 
initially added to the composite solution for fiber preparation. 
The drug loading efficiency and entrapment efficiency was 
calculated using the following equations:
Loading efficiency (%) =   Amount of CPT in composite fibers 
/Weight of composite mat × 100 
  (1)
Entrapment efficiency (%) = Amount of CPT in composite  
    fibers/Amount of CPT used for preparation  
of composite × 100  (2)
Electron probe microanalysis (EPMA) and energy 
dispersive X-ray analysis
The chemical composition of the CPT/Fe2O3-PLGA com-
posite fibers was analyzed by energy dispersive X-ray spec-
trometer (S-7400, Hitachi High technologies, Tokyo, Japan) 
equipped with SEM apparatus, whereas the distribution of 
elements was measured using EPMA (S-7400, Hitachi High 
technologies, Tokyo, Japan).
Thermogravimetric analysis (TgA)
The thermal stability of the samples was characterized by 
TGA (Pyris 1 TGA, PerkinElmer, Waltham, MA) under 
nitrogen with a flow rate of 20 mL/minute. The samples 
(∼2–5 mg) were heated in a platinum pan from 25°C–450°C 
at a scanning rate of 10 °C/minute.
Fourier transform infrared (FTIr)
The composition of samples was characterized by FTIR (Spec-
trum RX1, PerkinElmer) spectroscopy in the wave number 
range of 500–4000 cm−1 at a resolution of 4 cm−1. The dried 
samples were ground into powder by a fiber microtome and 
then blended with potassium bromide before pressing the 
mixture into ultrathin pellets. The change in chemical structure 
of electrospun mats was investigated by FTIR spectroscopy.
In vitro drug release, matrix degradation,  
and stability of encapsulated CPT
The CPT/Fe2O3-PLGA composite mat was exactly weighed 
(0.1 g) and immersed in 40 mL 0.1 M Gibco® phosphate 
buffered saline (PBS: pH 7.4; Invitrogen Life   Technologies, 
Carlsbad, CA) in order to obtain sink conditions. The suspension 
was kept in a thermostated shaker (SI-300R; Jeio Tech Co, Ltd, 
Seoul, Korea) that was maintained at 37°C and 100 rpm. At 
predetermined time intervals, 2 mL of the released solution 
was removed for analysis, and an equal amount of fresh buf-
fer solution was added back in. The CPT concentration in the 
release media was detected by UV-Vis spectrophotometer 
and the spectra obtained were analyzed by spectrophotometer 
software (Probe 2.21, UV-Vis ChemStation; Agilent Technolo-
gies). The analysis was carried out in duplicate and the CPT 
release (%) versus time (hours) profiles were then plotted. To 
evaluate the change in morphology of the CPT/Fe2O3-PLGA 
composite mat after drug release in PBS, a fraction of compos-
ite mat was taken out at a predetermined time interval (after 
30 days), rinsed with pure water to remove residual buffer salts, 
and dried in a vacuum desiccator (JEIOTECH Co. Ltd, South 
Korea). The morphology was observed by SEM as described 
above. To determine the stability of encapsulated CPT in the 
release medium, the composite mat was incubated for 3 weeks 
in PBS at 37°C with constant stirring. Aliquots (1 mL) were 
taken from the medium for scanning with UV-Vis spectro-
photometry according to a previously described method.24 
The ratios (A355/A368) were calculated from the intensity of 
the characteristic UV absorption of CPT lactone form (λmax 
355 nm) and carboxylate form (λmax 368 nm), and used to 
evaluate the stability of encapsulated CPT.
In vitro cytotoxicity assay
The CPT/Fe2O3-PLGA composite fibers and pristine PLGA 
fibers were sterilized under UV for 10 minutes. Mouse 
myoblast C2C12 (CRL 1772™; American Type Culture Col-
lection, Manassas, VA) cells were used as model cell lines 
and the cell viability was evaluated by Cell Counting Kit-8 
(Sigma-Aldrich) reagent. Briefly, cells were cultured in 
Dulbecco’s modified Eagle medium (pH 7.4, with 10% fetal 
bovine serum and 1% penicillin–streptomycin) in a humidified 
incubator (RCO3000T-5-VBC, Kendro Laboratory Products, 
Asheville-NC, USA) at 37°C with 5.0% carbon dioxide and 
95% air environment. The cell density of 1 × 104 cells/well 
was seeded in a 96-well tissue culture plate (Becton Dickson 
and Company, Franklin Lakes, NJ) and allowed to attach and 
grow in wells overnight before CPT/Fe2O3-PLGA composite 
treatment. When C2C12 reached ∼40% confluence, cells 
were treated with different concentrations (5 µg and 10 µg) 
of encapsulated CPT in composite matrix for a specific time 
(24, 48, and 72 hours) duration. Cell proliferation without 
drug treatment was set as the control. Cell viability was 
evaluated using a Cell Counting Kit-8 assay, in which 10 µL 
of water-soluble tetrazolium-8 (Cell Counting Kit-8) solution 
in each well (100 µL medium) was added and incubated for 
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4 hours at 37°C according to the manufacturer’s instructions. 
At the end of the experiment, absorbance was measured at 
450 nm for each well by a microplate spectrophotometer (model 
680; Bio-Rad Laboratories, Hercules, CA). Morphological 
alterations and cell damage were qualitatively investigated 
using a light phase contrast microscope (CX41; Olympus Cor-
poration, Tokyo, Japan) at magnification 40×, and the photos 
were taken at different time intervals by computerized color 
FOculus® IEEE 1394 digital camera (NET New Electronic 
Technology GmbH, Finning, Germany) using the DIXI image 
solution software (v1.0; DIXI Optics, Daejeon, Korea).
Results and discussion
Characterization
Figure 1 represents the preparation of the CPT/Fe2O3-PLGA 
composite fibers. Figure 2A–E show the SEM micrographs 
of the synthesized Fe2O3 nanoparticles, plain PLGA, and 
the CPT/Fe2O3-PLGA system at different magnifications. 
Electrospinning of PLGA solutions containing 4 weight percent 
of the polymer afforded well-defined ultrafine fibers with an 
average diameter of about 750 ± 30 nm (Figure 2A and B). 
The pristine PLGA electrospun fibers had a smooth surface 
and appeared well defined without any interconnection (point 
bonding) between the fibers. The CPT/Fe2O3-PLGA system 
appeared smooth with Fe2O3 nanoparticles, but no drug 
crystals, on the polymer surface (Figure 2C and D). This 
suggested that the drug was dispersed homogeneously in the 
electrospun fibers. The drug-loaded fibers showed increased 
diameter size as compared to drug-free fibers. Furthermore, 
the incorporation of the drug produced ultrafine fibers with 
cross linking between the fibers. The fiber diameter was in 
the range of 1 µm (± 30 nm) on incorporation of the drug, 
and the formation of point-bonded structures was observed 
throughout the mats. Enlargement of the fibers obtained from 
the CPT/Fe2O3-PLGA colloid is preliminary evidence for CPT 
incorporation inside the polymeric ultrafine fibers. The drug 
loading and encapsulation efficacy of the composite mat was 
found to be ∼3.8% and 75%, respectively. Earlier workers have 
reported that the affinity of loaded drugs to the polymeric 
matrix significantly affects drug loading capacity.25,26 In view 
of this, the promising values of encapsulation efficiency 
obtained for CPT in the current study could be related to 
the higher binding affinity of the Fe2O3-embedded PLGA 
matrix to CPT.
Motor
Magnetic Fe2O3 PLGA chain
CPT
CPT
Voltage supplier
Electrospinning setup
AV
CPT/Fe2O3−PLGA composite solution
CPT/Fe2O3−PLGA composite fiber
Rotating collector
Charged jet
Sol−gel solution
P
o
s
i
t
i
v
e
 
t
e
r
m
i
n
a
l
Electrospinning
Cu wire
Negative terminal
Syringe
CPT loaded Fe2O3
Fe2O3 nanoparticles
nanoparticles
Figure 1 Illustration for the preparation of camptothecin/iron(III) oxide-embedded poly(D,L-lactide-co-glycolide) composite fibers by electrospinning process.
Abbreviations: CPT, camptothecin; Cu, copper; Fe2O3, iron(III) oxide; PLgA, poly(D,L-lactide-co-glycolide).
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The morphology of the Fe2O3 nanoparticles examined 
by SEM was spherical (Figure 2E) and the average nanopar-
ticle size was found to be around 125 ± 15 nm. Figure 2F 
shows the energy dispersive X-ray spectrum of the CPT/
Fe2O3-PLGA composite fibers which contained carbon, 
oxygen, and iron; no other elemental impurity was detected, 
indicating that the final product was free of impurity and 
composed of CPT and Fe2O3. The inoculation of CPT into 
electrospun fibers was analyzed by UV fluorescence at 
wavelength 256 nm. As shown in the inset of Figure 2F, 
the electrospun composite mat emitted fluorescent light, 
suggesting the presence of CPT in the CPT/Fe2O3-PLGA 
composite mat. Noteworthy is that CPT nanoparticles could 
not be observed on the fiber surface, which indicates full 
encapsulation of the drug nanoparticles. The shift from the 
nonbonded to the point-bonded fiber morphology of the mat 
significantly affects the mechanical strength and stability 
of the mat, which is desirable for various applications.
In order to get indepth insight into the structural 
features of electrospun composite fibers, TEM analysis was 
performed. Figure 3A shows the TEM image of the com-
posite mat. The TEM image clearly demonstrates that the 
composite fibers contained Fe2O3 nanoparticles on the sur-
face and exhibited a distinct uniform stratum due to the 
presence of CPT on or near the surface of the composite 
fibers. CPT is basically hydrophobic in nature and the CPT/
polymer solution would carry excess charges and move to 
the outer region of the electrospinning jet due to the charge 
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Figure 2 Scanning electron microscopic images of (A and B) pristine poly(D,L-lactide-co-glycolide), (C and D) camptothecin/iron(III) oxide-embedded poly(D,L-lactide-co-
glycolide) composite ultrafine fibers, and (E) iron(III) oxide nanoparticles at different magnifications (yellow circles represent point bonding). (F) Energy dispersive X-ray 
spectrum of camptothecin/iron(III) oxide-embedded poly(D,L-lactide-co-glycolide) composite. The inset photographic images represent the (i) pristine and (ii) composite 
nanofibrous mats under ultraviolet fluorescence (λmax 256 nm).
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repulsion. As a result, an outer layer was formed in the CPT/
Fe2O3 composite fibers but no such layer was observed in 
pristine PLGA fibers. The successful blending of CPT and 
Fe2O3 with PLGA ultrafine fibers was further confirmed by 
EPMA (Figure 3B). The EPMA image clearly shows that 
carbon, oxygen, and nitrogen are the main components and 
Fe2O3 is also uniformly dispersed on the surface of the CPT/
Fe2O3-PLGA composite fibers.
The crystalline state of the incorporated drug in the 
electrospun composite fibers was examined by XRD. 
Figure 4 summarizes the results. Fe2O3 has rhombohedral 
structure (Joint Committee on Point Diffraction Standards 
number 892810) and pure CPT was crystalline with major 
peaks at 16.97 and 24.8 with many other minor peaks, 
whereas the PLGA polymer had no prominent peaks. The 
CPT/Fe2O3-PLGA also showed the same spectrum as that 
of plain PLGA except for two small peaks at 34.0 and 
36.0, which confirms the presence of Fe2O3   nanoparticles. 
  However, no distinct peak was observed for CPT. 
During the electrospinning process, the large surface area 
that is associated with nanofibers allowed fast and efficient 
solvent evaporation, which gave the incorporated drug 
limited time to recrystallize and favored the formation of 
an amorphous state.
1µm
1µm
CKa, 8
C O N Fe
OKa, 4N Ka, 7F eKa, 6
A
B
Figure 3 (A) representative transmission electron microscopic image of the camptothecin/iron(III) oxide-embedded poly(D,L-lactide-co-glycolide) composite. The inset 
image shows the uniform distribution of iron(III) oxide nanoparticles. red and blue arrows demonstrate the distinct camptothecin layer and iron(III) oxide nanoparticles, 
respectively. (B) Electron probe microanalysis mapping result of the camptothecin/iron(III) oxide-embedded poly(D,L-lactide-co-glycolide) composite. The purple square 
represents the selected area.
Abbreviations: C, carbon; Fe, iron; N, nitrogen; O, oxygen.
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Figure  4  X-ray  diffraction  patterns  of  (A)  free  camptothecin,  (B)  iron(III) 
oxide  nanoparticles,  (C)  electrospun  pristine  poly(D,L-lactide-co-glycolide),  and 
(D) camptothecin/iron(III) oxide-embedded poly(D,L-lactide-co-glycolide) composite 
fibers.
Note: The red dashed square represents the iron(III) oxide nanoparticle signals.
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The TGA thermograms of the pristine and CPT/Fe2O3-
PLGA ultrafine fibers are shown in Figure 5. As pointed out 
by the TGA, pure PLGA fibers decomposed up to 94.1% 
while CPT/Fe2O3-PLGA fibers showed 81.2% degradation 
in the temperature range of 200°C–350°C. This result shows 
that CPT/Fe2O3-PLGA fibers have relatively higher thermal 
stability than pristine PLGA, which may be due to the higher 
decomposition temperature of CPT and Fe2O3 nanoparticles. 
This shift towards a higher temperature due to the addition of 
CPT/Fe2O3 also supports that there is point-bonded structure 
in the composite mat due to the homogenous mixing of CPT 
with PLGA, as shown in the SEM images (Figure 2). To 
properly investigate the thermal properties, the first derivative 
plots of the TGA curves were established. A major peak was 
observed in both the pristine and CPT/Fe2O3-PLGA compos-
ite fibers (Figure 5 inset), which is due to the decomposition 
of the polymer.
FTIR spectroscopy was used to further characterize the 
composite fibrous mats. It is clear from the current results 
that the FTIR spectra (Figure 6) of pristine and composite 
electrospun mats were very similar. The peaks around 
2995 cm−1 and 2948 cm−1 were attributed to aliphatic carbon–
hydrogen stretching vibrations. Meanwhile, the strong peak 
at 1755 cm−1 was related to the absorption by an ester carbo-
nyl (carbon = oxygen) stretch from PLGA. The copolymer 
PLGA also had characteristic peaks at 1455 cm−1 (methyl 
group carbon–hydrogen stretching), two peaks at 1422 cm−1 
and 1383 cm−1 (wagging vibrations from saturated carbon–
hydrogen bonds), and carbon–oxygen peaks at 1265, 1180, 
1090, and 1048 cm−1.27,28 A broad peak at ∼571 cm−1 shows 
the presence of an iron–oxygen bond in the composite fibers 
(Figure 6C), which further confirms the incorporation of 
Fe2O3 in the composite mat.
In vitro drug release and degradation  
of CPT/Fe2O3-PLgA composite mat
In order to investigate the drug release characteristics from 
the CPT/Fe2O3-PLGA electrospun mats, experiments were 
carried out using PBS buffer as the release medium at a 
controlled temperature and rpm as described previously. 
Since CPT is a hydrophobic substance with scarce aqueous 
solubility, the release investigation was carried out under 
sink conditions, keeping the drug concentration below its 
solubility limit; duplicate samples were incubated in PBS. 
At intervals, samples (2 mL) were removed and the medium 
replenished to maintain the sink conditions. The amount of 
drug in the samples was measured by UV-vis spectra with 
a range of 200–500 nm. The release of CPT from the com-
posite fibers versus time of incubation is shown in Figure 7. 
The release kinetics can be illustrated in two stages: an ini-
tial burst release followed by a constant slow release. CPT 
released from the composite fibers showed a burst release 
during the first 5 hours, releasing a considerable amount 
of drug. Afterwards, a gradual increase in the cumulative 
release followed over the next few hours, reaching a plateau 
at ∼60 hours. This burst release could be attributed to the 
presence of CPT on or near the surface of the composite 
fibers (Figure 3A). This portion of CPT could be easily dif-
fused into the release medium and lead to burst effect. As 
depicted in Figure 7, a ∼19% initial burst release from the 
CPT/Fe2O3-PLGA composite followed by sustained release 
was observed during the 4-day incubation.
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Figure 5 Thermogravimetric analysis graphs of (A) camptothecin/iron(III) oxide-
embedded  poly(D,L-lactide-co-glycolide)  composite  and  (B)  pristine  poly(D,L-
lactide-co-glycolide) ultrafine fibers.
Note: The inset graph represents the corresponding first derivatives in nitrogen 
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Figure 6 Fourier transform infrared spectra of (A) camptothecin/iron(III) oxide-
embedded poly(D,L-lactide-co-glycolide) composite and (B) pristine camptothecin/
iron(III) oxide-embedded poly(D,L-lactide-co-glycolide) ultrafine fibers.
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Different researchers have developed a number of 
delivery systems such as microparticles, nanoparticles, 
liposomes, micelles, and miniemulsions to overcome the 
solubility and stability problems of CPT, besides chemical 
modifications.29–33 The need of a system to further improve 
the therapeutic efficacy of the drug and to reduce its toxic 
effects is continuously attracting research attention.   Different 
types of solid lipid nanoparticles have been developed for 
CPT delivery34 showing a higher cytotoxicity on cells than 
the free control. A novel biodegradable and biocompat-
ible CPT/polymer implant based on chitosan for sustained 
intratumoral release of the drug has been described.35 An 
approach to overcome the shortcomings of CPT and its 
analogs, especially their high systemic toxicity, is to load it 
into a delivery system such as CPT/Fe2O3-PLGA electrospun 
composite fibers which will protect the drug from hydroly-
sis and control its release over a prolonged period. Since 
the active drug is dispersed and not solubilized, there is no 
possibility of chemical reaction between the active drug and 
the PLGA matrix.
Figure 7 shows the CPT release profiles from the syn-
thesized blend system. A significant amount released from 
the CPT-loaded electrospun nanofibers; however, after an 
initial burst release, a sustained release was observed. CPT 
is highly hydrophobic and the CPT/polymer solution would 
carry excess charges and move to the outer region of the 
electrospinning jet due to the charge repulsion. The initial 
burst release is due to the drug molecules enriched close 
to the fiber surface during the electrospinning process or 
loosely associated with the fiber matrix. For the delivery 
of antineoplastic drugs, a certain amount of initial burst is 
actually required to achieve enough of the initial dosage. 
Of course, for the cancer cells that survive the initial stage, 
sustained drug release is necessary. The current investiga-
tion indicated the advantages of electrospun fibrous mats in 
enhancing the constant release of hydrophobic drugs due to 
the significantly higher surface area for the drug dissolution 
and carrier   erosion. Additionally, the electrospun mats can be 
cut to almost any size and fabricated into other shapes using 
different target geometries for clinical applications.36
The degradation behavior of the CPT/Fe2O3-PLGA 
blend system was determined in buffer solution with 
respect to the morphological changes of the fibrous 
mats. Prominent changes (swollen and diffused fibers) 
were observed in the morphology after incubation for 
30 days in PBS buffer (Figure 7 inset). Since carboxylate 
conversion limits the bioavailability and efficacy of CPT, 
maintenance of the lactone structure during preparation, 
storage, and release is a prerequisite for improved therapy. 
To know the stability of CPT in the composite matrix, 
the characteristic UV absorption of encapsulated CPT 
was monitored in PBS (pH 7.4). Native CPT was used 
as a control. The characteristic UV absorption (λmax) of 
CPT lactone and carboxylate form in CPT/Fe2O3-PLGA 
was observed at 355 nm and 368 nm, respectively, 
even after 3 weeks of incubation with PBS (Figure 7A), 
which suggests the stability of CPT in CPT/Fe2O3-PLGA 
composite. To further check the stability of CPT in the 
composite matrix, the A355/A368 ratios were calculated 
from the intensity of the maximum UV absorption of CPT 
lactone and carboxylate form. The results showed that the 
A355/A368 ratios of encapsulated CPT remained the same 
with increased incubation time. Moreover, the surface of the 
composite matrix was hydrophobic and CPT encapsulated 
in the ultrafine fibers was prevented from being exposed to 
the liquid medium. It is suggested that electrospun fibers 
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Figure 7 In vitro release profile of (A) camptothecin from electrospun camptothecin/
iron(III)  oxide-embedded  poly(D,L-lactide-co-glycolide)  composite  fibers  and 
(B) A355/A368 ratios of camptothecin/iron(III) oxide-embedded poly(D,L-lactide-
co-glycolide) composite mat against incubation time in phosphate buffered saline.
Note: The inset scanning electron microscopic image shows the camptothecin/
iron(III) oxide-embedded poly(D,L-lactide-co-glycolide) composite after incubation 
in phosphate buffered saline at 37°C for 30 days.
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could effectively release the lactone form of CPT which is 
beneficial for the enhancement of anticancer activity.
In vitro cytotoxicity assay
The cytotoxicity of the CPT/Fe2O3-PLGA composite mat was 
tested on C2C12 cell lines; free CPT and the pristine PLGA 
composite mat were kept as controls. Figure 8 summarizes 
the cell viability after 24, 48, and 72 hours of incubation. As 
depicted in Figure 8, ∼40% and 56% inhibition was observed 
after 24 hours of incubation in free CPT and CPT/Fe2O3-
PLGA samples (10 µg/well), respectively. No significant 
cytotoxicity of the unloaded PLGA mat was observed, indi-
cating that the toxicity towards the cells was a consequence of 
the CPT molecule. However, a slight decline was observed at 
72 hours with pristine PLGA. Moreover, it was also observed 
that the toxicity increased with an increase in concentration. 
Approximately 58% and 62%, 87% and 97% inhibition was 
observed at 5 µg/well and 10 µg/well with free CPT and 
CPT/Fe2O3-PLGA blend system, respectively, after 72 hours 
of incubation time. The data lead to the conclusion that 
the growth inhibition is concentration and time dependent. 
In particular, the CPT/Fe2O3-PLGA blend system showed 
a higher inhibition effect with respect to free CPT. The 
increased activity observed for the medicated composite 
fibers compared to that of free CPT could be explained by 
the increased stability of CPT caused by the interaction with 
Fe2O3/PLGA matrix. The complexed CPT is less prone to 
hydrolysis and the lactone ring is protected, which is essential 
for passive diffusion of the drug into cancer cells.
As is already known, the targeted delivery of antitumor 
agents adsorbed on the surface of magnetic nanoparticles 
is a promising alternative to conventional chemotherapy. 
The particles loaded with the drug are concentrated at the 
target site with the aid of an external magnet. The drugs are 
then released on the desired area.37 Therefore, the incredible 
enhancement of cell inhibition rates by the CPT/Fe2O3-
PLGA composite is due to the synergistic effect of novel 
Fe2O3/PLGA. The results from the current study indicate 
that the composite (CPT/Fe2O3-PLGA) system facilitated 
the accumulation and cellular uptake of CPT. Morphological 
alterations induced by CPT/Fe2O3-PLGA was also tested in 
C2C12 cells. Untreated cells were thin and elongated with 
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Figure 8 In vitro cytotoxicity of (A) free camptothecin and camptothecin/iron(III) oxide-embedded poly(D,L-lactide-co-glycolide) composite. Untreated C2C12 cells and 
cells treated with pristine poly(D,L-lactide-co-glycolide) were used as a control. representative phase contrast images of C2C12 cell lines (B) unexposed to, (C) exposed to 
5 µg, and (D) exposed to 10 µg camptothecin/iron(III) oxide-embedded poly(D,L-lactide-co-glycolide) composite.
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Abbreviations: CPT, camptothecin; PLgA, poly(D,L-lactide-co-glycolide).
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two tapering ends (Figure 7B). The incubation with CPT/
Fe2O3-PLGA composite fibers showed that C2C12 cells lost 
their common elongated shape and appeared in a form of 
numerous roughly rounded cells of variable size (Figure 7B). 
Areas devoid of cells were also recorded (Figure 7C). After 
incubation with CPT/Fe2O3-PLGA (10 µg/well), the cells 
fragmented to minute vesicles. Few rounded cells and some 
areas devoid of cells were also noticed in the same culture 
medium. The treatment led to the aggregation of dense 
irregular cellular debris. No intact cells were recognized in 
this medium, which indicates the occurrence of widespread 
cell death (Figure 7D).
Conclusion
To sum up, pristine PLGA and CPT/Fe2O3-PLGA composite 
mats were successfully prepared by a simple, cost-effective 
electrospinning technique. For the current investigation, 
CPT and C2C12 cells were chosen as the model drug and 
cell lines, respectively. The release profile of CPT from the 
Fe2O3-loaded PLGA composite fibrous mat and the matrix 
degradation behavior were also studied. The characterization 
of the synthesized CPT/Fe2O3-PLGA composite mat was 
carried out by SEM, energy dispersive X-ray spectrometry, 
EPMA, TEM, TGA, and XRD analysis. Moreover the medi-
cated electrospun fibers were evaluated for their cytotoxicity 
against C2C12 cells. The cytotoxicity assay indicated that 
the as-spun composite fibers had superior in vitro inhibi-
tion than the pristine CPT. The most probable reason for 
the enhanced activity is the synergistic effect of Fe2O3 and 
PLGA. The combination of magnetic and anticancer fea-
tures exhibited by the CPT/Fe2O3-PLGA composite can be 
exploited in medicine, where they can be used for targeted 
transport of the anticancer agent (CPT) and its subsequent 
removal by an external magnetic field. Physicochemical 
characterization results confirm that the loaded drug retained 
its biological functionality even after it had been subjected 
to a high electrical voltage, indicating that the composite 
medicated fibers developed in the current study have great 
potential in drug delivery and is a promising material for 
cancer chemotherapy. However, the in vivo behavior of the 
drug release from the electrospun composite fibers needs to 
be confirmed in future studies.
Acknowledgments
This work is supported by the grant from the Korean Ministry 
of Education, Science, and Technology (The Regional Core 
Research Program/Center for Healthcare Technology and 
Development, Chonbuk National University, Jeonju, Korea).
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG. Crystal 
structures of human topoisomerase I in covalent and noncovalent 
complexes with DNA. Science. 1998;279(5356):1504–1513.
  2.  Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB Jr, 
Stewart L. The mechanism of topoisomerase I poisoning by a 
camptothecin analogue. Proc Natl Acad Sci U S A. 2002;99(24): 
15387–15392.
  3.  Li SY, Adair KT. Camptotheca acuminata Decaisne (Xi Shu,   Chinese 
Happy Tree): A Promising Antitumor and Antiviral Tree for the 
21st Century. Nacogdoches, TX: Stephen F Austin State University; 
1994.
  4.  Oberlies NH, Kroll DJ. Camptothecin and taxol: historic achievements 
in natural products research. J Nat Prod. 2004;67(2):129–135.
  5.  Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA. 
Plant antitumor agents. I. The isolation and structure of camptothecin, 
a novel alkaloidal leukemia and tumor inhibitor from Camptotheca 
acuminata. J Am Chem Soc. 1966;88(16):3888–3890.
  6.  Fassberg J, Stella VJ. A kinetic and mechanistic study of the 
hydrolysis of camptothecin and some analogues. J Pharm Sci. 
1992;81(7):676–684.
  7.  Chourpa I, Millot JM, Sockalingum GD, Riou JF, Manfait M. 
Kinetics of lactone hydrolysis in antitumor drugs of camptothecin 
series as studied by fluorescence spectroscopy. Biochim Biophys Acta. 
1998;1379(3):353–366.
  8.  Venditto VJ, Simanek EE. Cancer therapies utilizing the camptothecin: 
a review of in vivo literature. Mol Pharm. 2010;7(2):307–349.
  9.  Lv G, He F, Wang X, et al. Novel nanocomposite of nano Fe3O4 and 
polylactide nanofibers for application in drug uptake and induction of cell 
death of leukemia cancer cells. Langmuir. 2008;24(5):2151–2156.
  10.  Lalloo A, Chao P, Hu P, Stein S, Sinko PJ. Pharmacokinetic and 
pharmacodynamic evaluation of a novel in situ forming poly(ethylene 
glycol)-based hydrogel for the controlled delivery of the camptothecins. 
J Control Release. 2006;112(3):333–342.
  11.  Zhang L, Yang M, Wang Q, et al. 10-Hydroxycamptothecin loaded 
nanoparticles: preparation and antitumor activity in mice. J Control 
Release. 2007;119(2):153–162.
  12.  Zahedi P, Rezaeian I, Ranaei-Siadat SO, Jafari SH, Supaphol PA. 
A review on wound dressings with an emphasis on electrospun nano-
fibrous polymeric bandages. Polym Adv Technol. 2010;21(2):77–95.
  13.  Reneker DH, Chun I. Nanometer diameter fibers of polymer produced 
by electrospinning. Nanotechnology. 1996;7:216–223.
  14.  Huang ZM, Zhang YZ, Kotaki M, Ramakrishna S. A review on polymer 
nanofibers by electrospinning and their applications in nanocomposites. 
Compos Sci Technol. 2003;63(15):2223–2253.
  15.  Greiner A, Wendorff JH. Electrospinning: a fascinating method 
for the preparation of ultrathin fibers. Angew Chem Int Ed Engl. 
2007;46(30):5670–5703.
  16.  Matsumura Y, Maeda H. A new concept for macromolecular therapeu-
tics in cancer chemotherapy: mechanism of tumoritropic accumula-
tion of proteins and the antitumor agent smancs. Cancer Res. 1986; 
46(12 Pt 1):6387–6392.
  17.  Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug 
Discov. 2003;2(5):347–360.
  18.  Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V . 
Iron oxide nanoparticles for sustained delivery of anticancer agents. 
Mol Pharm. 2005;2(3):194–205.
  19.  Lubbe AS, Alexiou C, Bergemann C. Clinical applications of magnetic 
drug targeting. J Surg Res. 2008;95:200–206.
  20.  Martina MS, Wilhem C, Lesieur S. The effect of magnetic targeting 
on the uptake of magnetic-fluid-loaded liposomes by human prostatic 
adenocarcinoma cells. Biomaterials. 2008;29(30):4137–4145.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1669
CPT/Fe2O3-embedded PLGA ultrafine composite fibersInternational Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of Nanomedicine 2012:7
  21.  Scarberry KE, Dickerson EB, McDonald JF, Zhang ZJ. Magnetic nano-
particle-peptide conjugates for in vitro and in vivo targeting and extrac-
tion of cancer cells. J Am Chem Soc. 2008;130(31):10258–10262.
  22.  Leuner C, Dressman J. Improving drug solubility for oral delivery using 
solid dispersion. Eur J Pharm Biopharm. 2000;50(1):47–60.
  23.  Zhu A, Yuan L, Jin W, et al. Polysaccharide surface modified Fe3O4 
nanoparticles for camptothecin loading and release. Acta Biomater. 
2009;5(5):1489–1498.
  24.  Zhao H, Lee C, Sai P, et al. 20-O-acylcamptothecin derivatives: evidence 
for lactone stabilization. J Org Chem. 2000;65(15):4601–4606.
  25.  Lee J, Cho EC, Cho K. Incorporation and release behavior of hydrophobic 
drug in functionalized poly(D,L-lactide)-block-poly(ethylene oxide) 
micelles. J Control Release. 2004;94(2–3):323–335.
  26.  Allen C, Maysinger D, Eisenberg A. Nano-engineering block 
copolymer aggregates for drug delivery. Colloids Surf B Biointerfaces. 
1999;16(1–4):3–27.
  27.  Liu F, Guo R, Shen M, Wang S, Shi X. Effect of processing variables 
on the morphology of electrospun poly(lactic acid)-co-(glycolic acid) 
nanofibers. Macromol Mater Eng. 2009;294(10):666–672.
  28.  Armentano I, Dottori M, Puglia D, Kenny JM. Effects of carbon 
nanotubes (CNTs) on the processing and in-vitro degradation of 
poly(DL-lactide-co-glycolide)/CNT films. J Mater Sci Mater Med. 
2008;19(6):2377–2387.
  29.  Hatefi A, Amsden B. Camptothecin delivery methods. Pharm Res. 
2002;19(10):1389–1399.
  30.  Shenderova A, Burke TG, Schwendeman SP. Stabilization of 
10-hydroxycamptothecin in poly(lactide-co-glycolide) microsphere 
delivery vehicles. Pharm Res. 1997;14(10):1406–1414.
  31.  Cortesi R, Esposito E, Maietti A, Menegatti E, Nastruzzi C. Formulation 
study for the antitumor drug camptothecin: liposomes, micellar solutions 
and a microemulsion. Int J Pharm. 1997;159(1):95–103.
  32.  Kunii R, Onishi H, Machida Y. Preparation and antitumor characteristics 
of PLA/(PEG-PPG-PEG) nanoparticles loaded with camptothecin. Eur 
J Pharm Biopharm. 2007;67(1):9–17.
  33.  Davis ME. Design and development of IT-101, a cyclodextrin 
containing polymer conjugate of camptothecin. Adv Drug Deliv Rev. 
2009;61(13):1189–1192.
  34.  Huang ZR, Hua SC, Yang YL, Fang JY. Development and evaluation 
of lipid nanoparticles for camptothecin delivery: a comparison of solid 
lipid nanoparticles, nanostructured lipid carriers, and lipid emulsion. 
Acta Pharmacol Sin. 2008;29(9):1094–1102.
  35.  Berrada M, Serreqi A, Dabbarh F, Owusu A, Gupta A, Lehnert S. 
A novel non-toxic camptothecin formulation for cancer chemotherapy. 
Biomaterials. 2005;26(14):2115–2120.
  36.  Verreck G, Chun I, Rosenblatt J, et al. Incorporation of drugs in an amor-
phous state into electrospun nanofibers composed of a water-insoluble, 
nonbiodegradable polymer. J Control Release. 2003;92(3):349–360.
  37.  Fernandez-Pacheco R, Marquina C, Valdivia JG, et al. Magnetic 
nanoparticles for local drug delivery using magnetic implants. J Magn 
Magn Mater. 2007;311(1):318–322.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1670
Amna et al